{"version":"1.0","provider_name":"Press Arabia","provider_url":"https:\/\/pressarabia.qa","author_name":"admin","author_url":"https:\/\/pressarabia.qa\/author\/admin01\/","title":"BioIntelliSense Closes Oversubscribed $45M Series B Financing Round to Scale Its Data-as-a-Service and Clinical Intelligence Platform - Press Arabia","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"OEGTW9Mypw\"><a href=\"https:\/\/pressarabia.qa\/biointellisense-closes-oversubscribed-45m-series-b-financing-round-to-scale-its-data-as-a-service-and-clinical-intelligence-platform\/\">BioIntelliSense Closes Oversubscribed $45M Series B Financing Round to Scale Its Data-as-a-Service and Clinical Intelligence Platform<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/pressarabia.qa\/biointellisense-closes-oversubscribed-45m-series-b-financing-round-to-scale-its-data-as-a-service-and-clinical-intelligence-platform\/embed\/#?secret=OEGTW9Mypw\" width=\"600\" height=\"338\" title=\"&#8220;BioIntelliSense Closes Oversubscribed $45M Series B Financing Round to Scale Its Data-as-a-Service and Clinical Intelligence Platform&#8221; &#8212; Press Arabia\" data-secret=\"OEGTW9Mypw\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","description":"Strategic funding will support company\u2019s growth and global expansion of continuous multi-parameter monitoring devices and data services for medical grade remote care at scale DENVER, July 28, 2021 \/PRNewswire\/ \u2014\u00a0BioIntelliSense, Inc., a continuous health monitoring and clinical intelligence company, today announced it has recently closed its Series B financing round that was significantly oversubscribed at [\u2026]","thumbnail_url":"https:\/\/ci6.googleusercontent.com\/proxy\/AndMHAwyfM9_jfimlPIz7E4u3EBpku6qZ4TkhOLBtIvU2SV9reMb7KyGcDmubeFNJoP9uUAd9BzTrVbcJMtjI3WwnhfrJnfPyexlP9UCh09BEGzf=s0-d-e1-ft#https:\/\/mma.prnewswire.com\/media\/1082814\/BioIntellisense_Logo.jpg"}